share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q:2024財年二季報
美股SEC公告 ·  2024/08/14 22:34

Moomoo AI 已提取核心訊息

60 Degrees Pharmaceuticals reported Q2 2024 product revenues of $124,972, up 110% from $59,532 in Q2 2023, driven by strong growth in Arakoda sales. Gross profit improved to $35,408 compared to a loss of $124,445 last year, with gross margin reaching 28.3%. U.S. pharmaceutical distributor accounted for 92% of net product sales.Operating expenses increased significantly to $4.2 million from $667K in Q2 2023, primarily due to $2.6 million in R&D costs related to the Kentucky Technology report and $390K for the planned babesiosis trial. General and administrative expenses rose to $1.1 million driven by higher compensation, insurance, and investor outreach costs.The company ended the quarter with $1.6 million in cash. Management estimates current funds will sustain operations through March 2025, excluding costs for commercial programs and clinical trials. The company recently raised additional capital through an ATM offering in July-August 2024, selling 677,819 shares for proceeds of $2 million. A 1:12 reverse stock split was implemented in August 2024 to address Nasdaq listing requirements.
60 Degrees Pharmaceuticals reported Q2 2024 product revenues of $124,972, up 110% from $59,532 in Q2 2023, driven by strong growth in Arakoda sales. Gross profit improved to $35,408 compared to a loss of $124,445 last year, with gross margin reaching 28.3%. U.S. pharmaceutical distributor accounted for 92% of net product sales.Operating expenses increased significantly to $4.2 million from $667K in Q2 2023, primarily due to $2.6 million in R&D costs related to the Kentucky Technology report and $390K for the planned babesiosis trial. General and administrative expenses rose to $1.1 million driven by higher compensation, insurance, and investor outreach costs.The company ended the quarter with $1.6 million in cash. Management estimates current funds will sustain operations through March 2025, excluding costs for commercial programs and clinical trials. The company recently raised additional capital through an ATM offering in July-August 2024, selling 677,819 shares for proceeds of $2 million. A 1:12 reverse stock split was implemented in August 2024 to address Nasdaq listing requirements.
60度藥品公司報告了2024年第二季度的產品收入爲124,972美元,較2023年第二季度的59,532美元增長了110%,這主要得益於阿拉科達銷售的強勁增長。毛利潤改善至35,408美元,而去年則出現了124,445美元的損失,毛利率達到28.3%。美國藥品分銷商佔淨產品銷售的92%。營業費用顯著增加至420萬,由2023年第二季度的66.7萬增長,主要由於科技報告相關的260萬研發成本和計劃中的巴貝斯蟲病試驗的39萬費用。一般和管理費用因工資、保險和投資者推廣費用的增加而上升至110萬。公司在本季度結束時現金爲160萬。管理層估計當前的所有基金類型將支持運營至2025年3月,但不包括商業項目和臨牀試驗的成本。公司最近通過在2024年7月至8月期間的ATM發行重新融資,出售677,819股股票,所得款項爲200萬。爲了滿足納斯達克上市要求,2024年8月實施了1:12的反向股票拆分。
60度藥品公司報告了2024年第二季度的產品收入爲124,972美元,較2023年第二季度的59,532美元增長了110%,這主要得益於阿拉科達銷售的強勁增長。毛利潤改善至35,408美元,而去年則出現了124,445美元的損失,毛利率達到28.3%。美國藥品分銷商佔淨產品銷售的92%。營業費用顯著增加至420萬,由2023年第二季度的66.7萬增長,主要由於科技報告相關的260萬研發成本和計劃中的巴貝斯蟲病試驗的39萬費用。一般和管理費用因工資、保險和投資者推廣費用的增加而上升至110萬。公司在本季度結束時現金爲160萬。管理層估計當前的所有基金類型將支持運營至2025年3月,但不包括商業項目和臨牀試驗的成本。公司最近通過在2024年7月至8月期間的ATM發行重新融資,出售677,819股股票,所得款項爲200萬。爲了滿足納斯達克上市要求,2024年8月實施了1:12的反向股票拆分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息